|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 95 No. 6 (March 15), 2000:
pp. 2031-2036
The opioid antagonist naloxone induces a shift from Type 2 to Type
1 cytokine pattern in BALB/cJ mice
Paola Sacerdote,
Barbara Manfredi,
Leda Gaspani, and
Alberto E. Panerai
From the Department of Pharmacology, University of Milano, Milan,
Italy.
Opioid peptides affect different immune functions. We present
evidence that these effects could be mediated by the modulation of
TH1/TH2 cytokine production. BALB/cJ mice were
immunized with 50 or 100 µg of the protein antigen keyhole-limpet
hemocyanin (KLH), and treated acutely or chronically with the opioid
antagonist naloxone. One and 2 weeks after immunization, the production
of cytokines by splenocytes was evaluated by in vitro restimulation with KLH. The acute and chronic treatment with the opioid receptor antagonist naloxone decreased the production of interleukin (IL)-4 by
splenocytes of BALB/cJ mice. In contrast, IL-2 and interferon- levels increased after naloxone treatment. Finally, the opioid antagonist diminished the serum immunoglobulin G anti-KLH antibody titers. These results suggest that naloxone increases TH1
and decreases TH2 cytokine production. The effect of
naloxone could be ascribed to the removal of the regulatory effects
exerted by endogenous opioid peptides, which could therefore activate
TH2 and suppress TH1 cytokines.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Jamali, M. Mahdavi, Z. M. Hassan, F. Sabahi, M. J. Farsani, T. Bamdad, H. Soleimanjahi, M. Motazakker, and S. Shahabi
A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine
Int. Immunol.,
March 1, 2009;
21(3):
217 - 225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Gironi, F Martinelli-Boneschi, P Sacerdote, C Solaro, M Zaffaroni, R Cavarretta, L Moiola, S Bucello, M Radaelli, V Pilato, et al.
A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis
Multiple Sclerosis,
September 1, 2008;
14(8):
1076 - 1083.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Borner, J. Kraus, A. Bedini, B. Schraven, and V. Hollt
T-Cell Receptor/CD28-Mediated Activation of Human T Lymphocytes Induces Expression of Functional {micro}-Opioid Receptors
Mol. Pharmacol.,
August 1, 2008;
74(2):
496 - 504.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Martucci, S. Franchi, D. Lattuada, A. E. Panerai, and P. Sacerdote
Differential involvement of RelB in morphine-induced modulation of chemotaxis, NO, and cytokine production in murine macrophages and lymphocytes
J. Leukoc. Biol.,
January 1, 2007;
81(1):
344 - 354.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Borner, V. Hollt, W. Sebald, and J. Kraus
Transcriptional regulation of the cannabinoid receptor type 1 gene in T cells by cannabinoids
J. Leukoc. Biol.,
January 1, 2007;
81(1):
336 - 343.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Kelschenbach, R. A. Barke, and S. Roy
Morphine Withdrawal Contributes to Th Cell Differentiation by Biasing Cells Toward the Th2 Lineage
J. Immunol.,
August 15, 2005;
175(4):
2655 - 2665.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Ait-Ali, V. Turquier, L. Grumolato, L. Yon, M. Jourdain, D. Alexandre, L. E. Eiden, H. Vaudry, and Y. Anouar
The Proinflammatory Cytokines Tumor Necrosis Factor-{alpha} and Interleukin-1 Stimulate Neuropeptide Gene Transcription and Secretion in Adrenochromaffin Cells via Activation of Extracellularly Regulated Kinase 1/2 and p38 Protein Kinases, and Activator Protein-1 Transcription Factors
Mol. Endocrinol.,
July 1, 2004;
18(7):
1721 - 1739.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Gironi, R Furlan, M Rovaris, G Comi, M Filippi, A E Panerai, and P Sacerdote
{beta} endorphin concentrations in PBMC of patients with different clinical phenotypes of multiple sclerosis
J. Neurol. Neurosurg. Psychiatry,
April 1, 2003;
74(4):
495 - 497.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Limiroli, L. Gaspani, A. E. Panerai, and P. Sacerdote
Differential morphine tolerance development in the modulation of macrophage cytokine production in mice
J. Leukoc. Biol.,
July 1, 2002;
72(1):
43 - 48.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Borner, V. Hollt, and J. Kraus
Involvement of Activator Protein-1 in Transcriptional Regulation of the Human {micro}-Opioid Receptor Gene
Mol. Pharmacol.,
April 1, 2002;
61(4):
800 - 805.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Kraus, C. Borner, E. Giannini, K. Hickfang, H. Braun, P. Mayer, M. R. Hoehe, A. Ambrosch, W. Konig, and V. Hollt
Regulation of {micro}-Opioid Receptor Gene Transcription by Interleukin-4 and Influence of an Allelic Variation within a STAT6 Transcription Factor Binding Site
J. Biol. Chem.,
November 16, 2001;
276(47):
43901 - 43908.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gironi, V. Martinelli, E. Brambilla, R. Furlan, A. E. Panerai, G. Comi, and P. Sacerdote
{beta}-Endorphin Concentrations in Peripheral Blood Mononuclear Cells of Patients With Multiple Sclerosis: Effects of Treatment With Interferon Beta
Arch Neurol,
August 1, 2000;
57(8):
1178 - 1181.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
